| Naslov: | Nature-inspired substituted 3-(imidazol-2-yl) morpholines targeting human topoisomerase IIα : dynophore-derived discovery |
|---|
| Avtorji: | ID Herlah, Barbara (Avtor)
ID Janežič, Matej (Avtor)
ID Ogris, Iza (Avtor)
ID Golič Grdadolnik, Simona (Avtor)
ID Kološa, Katja (Avtor)
ID Žabkar, Sonja (Avtor)
ID Žegura, Bojana (Avtor)
ID Perdih, Andrej (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://doi.org/10.1016/j.biopha.2024.116676
 PDF - Predstavitvena datoteka, prenos (7,99 MB)
MD5: BD6F61C36048CEF603C2D04E9673B6BD
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  KI - Kemijski inštitut
|
|---|
| Povzetek: | The molecular nanomachine, human DNA topoisomerase IIα, plays a crucial role in replication, transcription, and recombination by catalyzing topological changes in the DNA, rendering it an optimal target for cancer chemotherapy. Current clinical topoisomerase II poisons often cause secondary tumors as side effects due to the accumulation of double-strand breaks in the DNA, spurring the development of catalytic inhibitors. Here, we used a dynamic pharmacophore approach to develop catalytic inhibitors targeting the ATP binding site of human DNA topoisomerase IIα. Our screening of a library of nature-inspired compounds led to the discovery of a class of 3-(imidazol-2-yl) morpholines as potent catalytic inhibitors that bind to the ATPase domain. Further experimental and computational studies identified hit compound 17, which exhibited selectivity against the human DNA topoisomerase IIα versus human protein kinases, cytotoxicity against several human cancer cells, and did not induce DNA double-strand breaks, making it distinct from clinical topoisomerase II poisons. This study integrates an innovative natural product-inspired chemistry and successful implementation of a molecular design strategy that incorporates a dynamic component of ligand-target molecular recognition, with comprehensive experimental characterization leading to hit compounds with potential impact on the development of more efficient chemotherapies. |
|---|
| Ključne besede: | topoisomerase II, catalytic inhibitors, chemotherapy, DNA damage, cancer |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 01.06.2024 |
|---|
| Leto izida: | 2024 |
|---|
| Št. strani: | str. 1-18 |
|---|
| Številčenje: | Vol. 175, [article no.] 116676 |
|---|
| Izvor: | Biomedicine & pharmacotherapy |
|---|
| PID: | 20.500.12556/DiRROS-19029  |
|---|
| UDK: | 615.9 |
|---|
| ISSN pri članku: | 1950-6007 |
|---|
| DOI: | 10.1016/j.biopha.2024.116676 |
|---|
| COBISS.SI-ID: | 196316419 |
|---|
| Avtorske pravice: | © 2024 The Authors. |
|---|
| Opomba: | Soavtorji: Matej Janežič, Iza Ogris, Simona Golič Grdadolnik, Katja Kološa, Sonja Žabkar, Bojana Žegura, Andrej Perdih;
Nasl. z nasl. zaslona;
Opis vira z dne 22. 5. 2024;
|
|---|
| Datum objave v DiRROS: | 03.06.2024 |
|---|
| Število ogledov: | 243 |
|---|
| Število prenosov: | 114 |
|---|
| Metapodatki: |     |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
